research

An already approved medication used for bladder problems might help to treat multiple sclerosis, according to researchers at the State University of New York at Buffalo. Lead author Fraser J. Sim, PhD, Assistant Professor in the Department of Pharmacology and Toxicology in the University at Buffalo…

Compared to healthy people, women with multiple sclerosis (MS) may have inferior levels of certain antioxidants and nutrients with anti-inflammatory properties, including vitamin E and folate, according to a new study funded by the National Institute of Neurological Disorders and Stroke (NINDS). A research team led by Dr. Sandra…

Coffee Drinking may confer the side-benefit of lowering the risk of developing multiple sclerosis (MS) in susceptible individuals, according to a meta-analysis of Swedish and American studies to be presented at the American Academy of Neurology’s 67th Annual Meeting to be held April 18-25, 2015 at the…

A newly discovered molecule could play a pivotal role in inflammatory diseases, including multiple sclerosis, according to researchers at Trinity College Dublin and the University of Queensland Australia. The study was published in the journal Nature Medicine, and describes a molecule known as MCC950 that can suppress the ‘NLRP3 inflammasome’,…

The Strategic Pharma-Academic Research Consortium for Translational Medicine has awarded its first grants totaling more than $1.9 million to support research projects dedicated to autoimmune diseases. Among the recipients is researcher Yanjiao Zhou, Ph.D., who is leading a study at Washington University in St. Louis (WUSTL) focused on multiple sclerosis (MS), as…

Dr.  Jacob Sosnoff wants to know more about falling — something that few multiple sclerosis (MS) researchers focus on, even though it is a daily threat for many people with the disease. Sosnoff, an Associate Professor in the Department of Kinesiology and Community Health at the …

A new study entitled “Mercury Exposure and Antinuclear Antibodies among Females of Reproductive Age in the United States” suggests mercury exposure by seafood may increase the risk of developing autoimmune diseases in women. The study was published in the journal Environmental Health Perspectives. Autoimmune disorders…

An international group of researchers from the Center for Brain Research at the MedUni Vienna have published a paper in the Lancet Neurology journal titled “Pathological mechanisms in progressive multiple sclerosis,” documenting the pathological progress of MS since its early stages to what is known about…

A recent study led by researchers at the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada revealed a promising new method for multiple sclerosis (MS) treatment. The study was published in the journal Annals of Clinical and Translational Neurology and is…

 A study published by a team of investigators at the University of Tokyo’s Institute of Medical Science and Osaka University’s Graduate School of Engineering presented new evidence demonstrating how Toll-like receptor 9 (TLR9) binds to pathogenic DNA, turning on the functions of the innate immune…

A new study suggests that different types of physical activity might help the mental processes of people with multiple sclerosis. The research comes from the University of Illinois and the State University of New York at Buffalo, and appeared in the February 6th issue of the…

A study from German researchers might help to determine how multiple sclerosis is assessed in treatment trials. Published February 6 in the journal PLoS ONE, the study is titled “Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts –…

What may work better than existing drugs to treat severe multiple sclerosis? Stem cells. A phase 2 clinical study from an international group of research centers compared head-to-head autologous hematopoietic stem cell transplantation (AHSCT) and mitoxantrone in treating patients with secondary progressive or relapsing-remitting multiple sclerosis. The findings showed that…

Under development at Innate Immunotherapeutics is a special drug candidate to treat secondary progressive multiple sclerosis (SPMS). Currently, no viable therapies exist for SPMS — only less-effective means to treat SPMS patients through drugs designed for relapse-remitting multiple sclerosis — making the prospect of Innate’s experimental SPMS therapy a…

Nonprofit organization, Accelerated Cure Project for Multiple Sclerosis, is launching a national campaign called iConquerMS, which was designed by and for multiple sclerosis patients to raise awareness of the importance of health data and supporting research. On the iConquerMS portal, patients can…

Several renowned scientists working on multiple sclerosis (MS) recently joined forces to discuss and highlight the progress and knowledge gaps related to MS research, the prospects of finding a cure for the disease, and a strategy to reduce the burden the disease places on patients. A series of articles was published by the researchers in the…

Phoenix, Arizona-based Creative Medical Health (CMH) has just announced it has submitted a patent application for its proprietary mesenchymal stem cell pipeline product, indicated for autoimmune diseases. The company is already preparing to launch the product into its first line of clinical tests, which will…

The 2012 and 2014 ballots approving legalization of cannabis in four U.S. states have stirred the pot, so to speak, on a wide range of issues and nuances related to the herb — not least marijuana’s clinical use as a therapeutic agent. Medical marijuana remains a topic of debate…

Acorda Therapeutics, Inc. has released results from a Phase 1 clinical trial of rHIgM22 for multiple sclerosis, showing that the medication is safe and produces few side effects. rHIgM22 is a medication that may induce the re-wrapping of the myelin sheath that surround nerve cells,…

MicroConstants China, Inc., a company that provides preclinical, clinical, and consulting services to biotechnology and pharmaceutical companies, has just announced it has acquired international rights to the development of AA98 antibody pipeline products, indicated for the treatment of several types of cancer, multiple sclerosis, and age related macular degeneration…

MediciNova, Inc., has announced the acceptance of an abstract describing their ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS). The poster is to be presented at the American Academy of Neurology (AAN) 67th Annual Meeting, April 18 – 25, 2015 in Washington, DC. The presentation is titled…

Drug development company Rock Creek Pharmaceuticals, Inc. recently announced that a new clinical trial application with the United Kingdom’s Medicines Healthcare Products Regulatory Agency (MHRA) has been approved. The company is set to proceed with a Phase I study of its flagship pipeline product, Anatabine Citrate, a chemical that is found naturally…

A new study on the association between Helicobacter pylori and multiple sclerosis (MS) entitled “Helicobacter pylori infection as a protective factor against multiple sclerosis risk in females” was published in the Journal of Neurology, Neurosurgery & Psychiatry by Marzena J. Fabis Pedrini from the Centre…

A report by Bloomberg News‘ Caroline Chen says multinational biotech firm Biogen Idec Inc. is teaming up with Internet and IT colossus Google, pooling efforts to research environmental and biological factors potentially associated with Multiple Sclerosis (MS) progression. Ms. Chen notes that the Biogen Idec relationship is…

Teva Pharmaceutical Industries Ltd. recently made a major announcement on the U.S. Supreme Court‘s ruling on the matter of “Teva Pharmaceuticals USA, Inc. et al. Petitioners v. Sandoz Inc. et al. that reversed the Federal Circuit Court’s judgment of invalidity…

A study from a team of researchers at the Kessler Foundation provides new findings on multiple sclerosis (MS). According to the study, published in the journal Frontiers in Neurology, cognitive fatigue exhibited by MS patients is related to the length of the task they are involved in. Fatigue…

A new research study indicates that in patients with relapsing-remitting multiple sclerosis (MS), treatment with nonmyeloablative hematopoietic stem cell transplantation leads to improvement in neurological impairment and quality of life. The study, entitled “Association of Nonmyeloablative Hematopoietic Stem Cell Transplantation With Neurological Disability in Patients With Relapsing-Remitting Multiple…

Biopharmaceutical company Receptos, Inc. has enrolled the first participant with relapsing multiple sclerosis (RMS) in its SUNBEAM phase 3 trial, which will evaluate the potential therapy RPC1063 in patients who suffer from the disease. The company’s phase 3 RADIANCE trial, also…

Amarantus BioScience Holdings, Inc. has announced the acquisition of DioGenix, Inc., which will be merged as a new foundational asset into a growing neuro-diagnostic division at Amarantus called Amarantus Diagnostics. Amarantus BioScience is dedicated to developing novel neurological diagnostic tests and therapy options in the fields of neurology, psychiatry, ophthalmology and regenerative diseases, including multiple…

MedDay, a biotechnology company that develops new drugs for nervous system disorders, announced an update on the progress of its development pipeline with its lead product MD1003 for the treatment of primary and secondary progressive multiple sclerosis (MS). The first study is expected to be complete in early 2015, while…